real-world multicenter study of caplacizumab in patients with acquired ttp
Published 1 year ago • 128 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
3:56
results of the phase ii titan study of caplacizumab in patients with attp
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
2:06
thromboembolic event rates in patients with pv: a real-world analysis
-
4:13
real-world study determining the safety and efficacy of teclistamab in r/r multiple myeloma
-
1:43
real-world outcomes of teclistamab for r/r multiple myeloma
-
6:17
thrombotic thrombocytopenic purpura (ttp) part 1: basics
-
1:55
piccolo xpress with capillary tube
-
1:02:01
june 2023 labcop extended echo session: the world health assembly diagnostic capacity resolution
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
1:33
teclistamab for multiple myeloma in us hospitals: real-world data analysis
-
2:00
real-world bortezomib prescribing patterns and outcomes in ndmm
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
1:55
the real-world efficacy of brentuximab vedotin consolidation post-autosct in r/r hl
-
1:44
real-world outcomes of brexu-cel for r/r b-all: evidence from the cibmtr registry
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
3:58
extended follow-up of glofitamab monotherapy in r/r lbcl: durability of cr and likelihood of crs
-
0:45
difference between quality of life & patient-reported outcomes
-
1:31
strategies to minimize the occurrence of crs and icans in patients treated with car-t therapy
-
0:59
genomics throughout our lives
-
2:25
real-world study of tixagevimab/cilgavimab in pre-exposure prophylaxis for allosct recipients
-
2:42
a look inside the lab: flow cytometer
-
2:26
an insight into the aims of the eurasian hematology-oncology group